Results 1 to 7 of 7

Thread: AMZB Patent Approval for Treating HIV Infection

  1. Default AMZB Patent Approval for Treating HIV Infection

    Amazon Biotech, Inc. Announces Patent Approval for a Unique Formulation and Method of Treating HIV Infection

    NEW YORK, NY -- (MARKET WIRE) -- 09/05/06 -- Amazon Biotech, Inc. (OTCBB: AMZB) (FRANKFURT: B2D.F) today announced that it has a Notice of Allowance from the UnitedStates Patent and Trademark Office, advising that Amazon's application forpatent protection of its investigative drug named AMZ0026 has beenapproved.

    AMZ0026, a therapeutic herbal composition, is Amazon Biotech's primary drugcandidate and is currently approved by the FDA to undergo Phase I/IIstudies in humans. AMZ0026 has been shown to exhibit potentialtherapeutically beneficial effects on the immune system of immunodeficientHIV/AIDS patients, particularly with respect to elevation of CD4 levels inpreliminary clinical case studies.

  2. Default

    Dr. Mechael Kanovsky, President of Amazon Biotech, stated, "We are verypleased to receive the notice of allowance. We believe that this eventsignificantly strengthens our intellectual property rights and increasesour potential value."

    About Amazon Biotech, Inc.

    Amazon Biotech, Inc. is a natural plant pharmaceutical company, primarilydeveloping immune modulator drugs. AMZ0026 is the company's first suchdrug, which is to be used for the treatment of HIV/AIDS. The company planson initiating Phase I/II clinical studies of AMZ0026 in the near future,with an eventual goal of attracting a joint venture partner with a majorpharmaceutical company in Phase III trials, or follow the FDA Fast Trackprogram to market. Amazon Biotech specializes in natural plantpharmaceutical drugs and is focused on bringing healthier pharmaceuticaldrugs to market.

  3. Default

    "Safe-Harbor" Statement Under the Private Securities Litigation Reform Actof 1995 This press release contains forward-looking information within themeaning of Section 21E of the Securities Exchange Act of 1934, includingstatements regarding any potential sales of products as well as statementsthat include the words "believes," "expects," "anticipates," or similarexpressions. Such forward-looking statements involve known and unknownrisks, uncertainties and other factors that may cause the actual results,performance or achievements of Amazon Biotech, to differ materially fromthose implied or expressed by such forward-looking statements. Such factorsinclude, among others, the risk factors included in Amazon Biotech'ssubsequent reports filed with the Securities and Exchange Commission underthe Exchange Act. This press release speaks as of the date first set forthabove and Amazon Biotech assumes no responsibility to update theinformation included herein for events occurring after the date hereof.

  4. Default

    NEW YORK, NY -- (MARKET WIRE) -- 09/05/06 -- Amazon Biotech, Inc. (OTCBB: AMZB) (FRANKFURT: B2D.F) today announced that it has a Notice of Allowance from the UnitedStates Patent and Trademark Office, advising that Amazon's application forpatent protection of its investigative drug named AMZ0026 has beenapproved.

    AMZ0026, a therapeutic herbal composition, is Amazon Biotech's primary drugcandidate and is currently approved by the FDA to undergo Phase I/IIstudies in humans. AMZ0026 has been shown to exhibit potentialtherapeutically beneficial effects on the immune system of immunodeficientHIV/AIDS patients, particularly with respect to elevation of CD4 levels inpreliminary clinical case studies.

    Dr. Mechael Kanovsky, President of Amazon Biotech, stated, "We are verypleased to receive the notice of allowance. We believe that this eventsignificantly strengthens our intellectual property rights and increasesour potential value."

  5. Default

    About Amazon Biotech, Inc.

    Amazon Biotech, Inc. is a natural plant pharmaceutical company, primarilydeveloping immune modulator drugs. AMZ0026 is the company's first suchdrug, which is to be used for the treatment of HIV/AIDS. The company planson initiating Phase I/II clinical studies of AMZ0026 in the near future,with an eventual goal of attracting a joint venture partner with a majorpharmaceutical company in Phase III trials, or follow the FDA Fast Trackprogram to market. Amazon Biotech specializes in natural plantpharmaceutical drugs and is focused on bringing healthier pharmaceuticaldrugs to market.

  6. Default

    Amazon Biotech, Inc. (OTCBB: AMZB) a development stage company, engages in the research and development of all-natural drugs in the United States. The company owns the rights to a HIV/AIDS drug, AMZ 0026, a naturally derived pharmaceutical product, consisting of 11 natural plant substances that enable metabolic processes to support immune system function. In addition, it owns the rights to a natural hair growth product, AMZ HG001, which contains proprietary herbal ingredients. The company is based in New York City. With 37.59 million shares outstanding and 30,698 shares declared short as of August 2006, there is a failure to deliver in shares of AMZB.

  7. Default

    "Safe-Harbor" Statement Under the Private Securities Litigation Reform Actof 1995 This press release contains forward-looking information within themeaning of Section 21E of the Securities Exchange Act of 1934, includingstatements regarding any potential sales of products as well as statementsthat include the words "believes," "expects," "anticipates," or similarexpressions. Such forward-looking statements involve known and unknownrisks, uncertainties and other factors that may cause the actual results,performance or achievements of Amazon Biotech, to differ materially fromthose implied or expressed by such forward-looking statements. Such factorsinclude, among others, the risk factors included in Amazon Biotech'ssubsequent reports filed with the Securities and Exchange Commission underthe Exchange Act. This press release speaks as of the date first set forthabove and Amazon Biotech assumes no responsibility to update theinformation included herein for events occurring after the date hereof.

Posting Permissions

  • You may not post new threads
  • You may not post replies
  • You may not post attachments
  • You may not edit your posts
  •